SGLT2 Inhibitors
5 drugs in this class, prescribed by 119,800 Medicare Part D providers.
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$5.45B
Total Cost
5,223,231
Claims
5
Drugs
$1,043
Avg Cost/Claim
Key Insights
- Most expensive per prescription: Jardiance at $1,074/claim
- Most prescribed: Jardiance with 3,334,784 claims
- This class represents 2.0% of total Medicare Part D spending
All SGLT2 Inhibitors Drugs
| Drug | Cost | Claims |
|---|---|---|
| Empagliflozin | $3.58B | 3,334,784 |
| Dapagliflozin Propanediol | $1.65B | 1,666,200 |
| Empagliflozin/Metformin Hcl | $119.7M | 121,366 |
| Canagliflozin | $63.7M | 66,550 |
| Empagliflozin/Linagliptin | $32.6M | 34,331 |